Form 4: Arcellx CFO Michelle Gilson Reports Merger Transactions

Arcellx, Inc. Chief Financial Officer Michelle Gilson has filed a Form 4 detailing transactions related to the company's merger with Gilead Sciences, Inc.

Summary

• This filing reports transactions by Michelle Gilson, Chief Financial Officer of Arcellx, Inc., on April 28, 2026, in connection with the company's merger with Gilead Sciences, Inc.
• The merger involved an exchange of Arcellx common stock for a cash payment of $115.00 per share plus one Contingent Value Right (CVR) per share, representing a potential additional $5.00 payment.
• Various stock options and restricted stock units held by Ms. Gilson were canceled and converted into rights to receive cash payments and CVRs based on the merger terms.
• Specifically, stock options with exercise prices below $115.00 were converted into a cash payment equal to the difference between $115.00 and the exercise price, plus a CVR per share.
• Restricted stock units, including performance-based units, were converted into a cash payment equal to $115.00 per share, plus a CVR per share, with performance-based vesting determined at the time of the merger.
• Ms. Gilson also holds shares indirectly through a family charitable foundation, where she serves as President and has voting and investment power.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it confirms the completion of a significant acquisition with a substantial cash payout and potential future upside via CVRs for shareholders and management.

Positives

• The merger provides a significant cash payout of $115.00 per share to Arcellx shareholders, including Ms. Gilson.
• The inclusion of a Contingent Value Right (CVR) offers potential for additional future payments of $5.00 per share.
• All outstanding stock options and restricted stock units held by Ms. Gilson were converted into valuable cash and CVR rights, reflecting the merger's terms.

Negatives

• The filing details the cancellation of existing stock options and restricted stock units, which are replaced by cash and CVRs, effectively ending these equity-based incentives in their original form.

Risks

• The realization of the $5.00 CVR payment is contingent on specific terms and conditions outlined in the contingent value rights agreement, implying uncertainty regarding its receipt.
• The merger agreement itself represents a significant change for the company and its stakeholders, with potential integration challenges and strategic shifts under new ownership.

Future Outlook

The future outlook for Arcellx is now tied to Gilead Sciences following the completion of the merger. The CVR provides a contingent future payment to former shareholders, dependent on the achievement of certain conditions.

Management Comments

• The filing details the conversion of stock options and RSUs into cash and CVRs as per the merger agreement.
• Shares held by a family charitable foundation, of which the Reporting Person serves as President, are noted, with the Reporting Person retaining voting and investment power.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a significant event in the biotechnology sector, specifically the acquisition of Arcellx, Inc. by Gilead Sciences, Inc. Such acquisitions are common in the industry as larger pharmaceutical companies seek to bolster their pipelines with innovative assets from smaller, specialized biotechs. The terms of the merger, including the cash and CVR components, are typical for such transactions, aiming to provide immediate value while retaining some upside for former shareholders.

Comparison to Industry Standards

• The acquisition of Arcellx by Gilead Sciences at $115.00 per share plus a CVR is a substantial valuation, reflecting the perceived value of Arcellx's pipeline in the competitive biopharmaceutical landscape.
• The structure of the deal, involving a cash component and a contingent value right, is a common practice in M&A within the pharmaceutical and biotechnology sectors. Companies like Pfizer, Merck, and Bristol Myers Squibb have utilized similar deal structures in their acquisitions of smaller biotech firms to bridge valuation gaps and incentivize sellers.
• The specific CVR value of $5.00 per share is subject to the achievement of milestones, a standard mechanism to align the interests of acquirer and target shareholders post-acquisition.

Stakeholder Impact

• Shareholders: Receive $115.00 cash per share plus a CVR, representing a significant return on investment.
• Employees: Their roles and future employment are now under Gilead Sciences' management, with potential changes in organizational structure and benefits.
• Management: Ms. Gilson and other executives have had their equity holdings converted into cash and CVRs, reflecting the terms of the merger.
• Creditors: The financial obligations of Arcellx will be assumed by Gilead Sciences, providing a strong credit backing.

Next Steps

• The integration of Arcellx into Gilead Sciences is the primary next step.
• Shareholders will await the potential payout of the Contingent Value Rights based on the achievement of specified milestones.

Key Dates

Recommendation

This filing is a Form 4 reporting transactions related to a completed merger. The share price of Arcellx will no longer be independently traded as it has been acquired. For existing shareholders, the recommendation is to hold and await the potential CVR payout, as the immediate cash component has been realized. For potential investors, the opportunity to invest in Arcellx directly has passed; investment would now be in Gilead Sciences.

Keywords

Arcellx, ACLX, Form 4, SEC Filing, Merger, Gilead Sciences, Michelle Gilson, Chief Financial Officer, Stock Options, Restricted Stock Units, Contingent Value Right, CVR, Beneficial Ownership